Z. M. Younossi, A. B. Koenig, D. Abdelatif, Y. Fazel, L. Henry et al., Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, vol.64, issue.1, pp.73-84, 2016.

J. T. Haas, S. Francque, and B. Staels, Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease, Annual Review of Physiology, vol.78, issue.1, pp.181-205, 2016.

M. Eslam, A. J. Sanyal, J. George, A. J. Sanyal, B. Neuschwander-tetri et al., MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease, Gastroenterology, vol.158, issue.7, pp.1999-2014.e1, 2020.

S. Romeo, J. Kozlitina, C. Xing, A. Pertsemlidis, D. Cox et al., Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease, Nature Genetics, vol.40, issue.12, pp.1461-1465, 2008.

J. Kozlitina, E. Smagris, S. Stender, B. G. Nordestgaard, H. H. Zhou et al., Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease, Nature Genetics, vol.46, issue.4, pp.352-356, 2014.

N. Chalasani, X. Guo, R. Loomba, M. O. Goodarzi, T. Haritunians et al., Genome-Wide Association Study Identifies Variants Associated With Histologic Features of Nonalcoholic Fatty Liver Disease, Gastroenterology, vol.139, issue.5, pp.1567-1576.e6, 2010.

R. M. Mancina, P. Dongiovanni, S. Petta, P. Pingitore, M. Meroni et al., The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent, Gastroenterology, vol.150, issue.5, pp.1219-1230.e6, 2016.

A. Mantovani, E. Scorletti, A. Mosca, A. Alisi, C. D. Byrne et al., Complications, morbidity and mortality of nonalcoholic fatty liver disease, Metabolism, vol.111, p.154170, 2020.

F. Baratta, D. Pastori, F. Angelico, A. Balla, A. M. Paganini et al., Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study, Clinical Gastroenterology and Hepatology, vol.18, issue.10, pp.2324-2331.e4, 2020.

D. H. Sinn, D. Kang, Y. Chang, S. Ryu, S. J. Cho et al., Non?alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study, Journal of Gastroenterology and Hepatology, vol.35, issue.5, pp.833-839, 2019.

H. Yoshitaka, M. Hamaguchi, T. Kojima, T. Fukuda, A. Ohbora et al., Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease, Medicine, vol.96, issue.18, p.e6712, 2017.

G. Targher, C. D. Byrne, A. Lonardo, G. Zoppini, and C. Barbui, Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis, Journal of Hepatology, vol.65, issue.3, pp.589-600, 2016.

S. Wu, F. Wu, Y. Ding, J. Hou, J. Bi et al., Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis, Scientific Reports, vol.6, issue.1, p.33386, 2016.

Y. Liu, G. Zhong, H. Tan, F. Hao, and J. Hu, Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis, Scientific Reports, vol.9, issue.1, p.11124, 2019.

P. Libby, J. E. Buring, L. Badimon, G. K. Hansson, J. Deanfield et al., Atherosclerosis, Nature Reviews Disease Primers, vol.5, issue.1, p.56, 2019.
URL : https://hal.archives-ouvertes.fr/hal-01207988

Y. Chang, S. Ryu, K. Sung, Y. K. Cho, E. Sung et al., Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study, Gut, vol.68, issue.9, pp.1667-1675, 2018.

E. Oni, M. J. Budoff, I. Zeb, D. Li, E. Veledar et al., Nonalcoholic Fatty Liver Disease Is Associated With Arterial Distensibility and Carotid Intima-Media Thickness: (from the Multi-Ethnic Study of Atherosclerosis), The American Journal of Cardiology, vol.124, issue.4, pp.534-538, 2019.

D. Kapuria, V. K. Takyar, O. Etzion, P. Surana, J. H. O'keefe et al., Association of Hepatic Steatosis With Subclinical Atherosclerosis: Systematic Review and Meta?Analysis, Hepatology Communications, vol.2, issue.8, pp.877-887, 2018.

D. H. Sinn, D. Kang, Y. Chang, S. Ryu, S. Gu et al., Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study, Gut, vol.66, issue.2, pp.323-329, 2016.

J. Zheng, Y. Zhou, K. Zhang, Y. Qi, S. An et al., Association between nonalcoholic fatty liver disease and subclinical atherosclerosis: a cross-sectional study on population over 40 years old, BMC Cardiovascular Disorders, vol.18, issue.1, p.147, 2018.

Z. Xin, Y. Zhu, S. Wang, S. Liu, M. Xu et al., Associations of subclinical atherosclerosis with nonalcoholic fatty liver disease and fibrosis assessed by non?invasive score, Liver International, vol.40, issue.4, pp.806-814, 2020.

P. H. Harada, I. J. Bensenõr, L. F. Drager, A. C. Goulart, J. G. Mill et al., Non-alcoholic fatty liver disease presence and severity are associated with aortic stiffness beyond abdominal obesity: The ELSA-Brasil, Atherosclerosis, vol.284, pp.59-65, 2019.

S. B. Lee, G. Park, J. B. Lee, B. U. Lee, J. H. Park et al., Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study, Journal of Hepatology, vol.68, issue.5, pp.1018-1024, 2018.

B. K. Koo, M. A. Allison, M. H. Criqui, J. O. Denenberg, and C. M. Wright, The association between liver fat and systemic calcified atherosclerosis, Journal of Vascular Surgery, vol.71, issue.1, pp.204-211.e4, 2020.

H. E. Park, H. Lee, S. Choi, M. Kwak, J. I. Yang et al., Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter, Journal of Gastroenterology, vol.54, issue.3, pp.271-280, 2018.

S. H. Moon, T. S. Noh, Y. S. Cho, S. P. Hong, S. H. Hyun et al., Association Between Nonalcoholic Fatty Liver Disease and Carotid Artery Inflammation Evaluated by 18F-Fluorodeoxyglucose Positron Emission Tomography, Angiology, vol.66, issue.5, pp.472-480, 2014.

H. J. Lee, C. H. Lee, S. Kim, S. Y. Hwang, H. C. Hong et al., Association between vascular inflammation and non-alcoholic fatty liver disease: Analysis by 18F-fluorodeoxyglucose positron emission tomography, Metabolism, vol.67, pp.72-79, 2017.

P. K. Luukkonen, A. Nick, M. Hölttä-vuori, C. Thiele, E. Isokuortti et al., Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids, JCI Insight, vol.4, issue.16, p.127902, 2019.

M. C. Brouwers, N. Simons, C. D. Stehouwer, G. H. Koek, N. C. Schaper et al., Relationship Between Nonalcoholic Fatty Liver Disease Susceptibility Genes and Coronary Artery Disease, Hepatology Communications, vol.3, issue.4, pp.587-596, 2019.

E. K. Speliotes, L. M. Yerges-armstrong, J. Wu, R. Hernaez, L. J. Kim et al., Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits, PLoS Genetics, vol.7, issue.3, p.1001324, 2011.

Q. M. Anstee, R. Darlay, S. Cockell, M. Meroni, O. Govaere et al., Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort?, Journal of Hepatology, vol.73, issue.3, pp.505-515, 2020.

K. L. Donnelly, C. I. Smith, S. J. Schwarzenberg, J. Jessurun, M. D. Boldt et al., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease, Journal of Clinical Investigation, vol.115, issue.5, pp.1343-1351, 2005.

J. E. Lambert, M. A. Ramos?roman, J. D. Browning, and E. J. Parks, Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease, Gastroenterology, vol.146, issue.3, pp.726-735, 2014.

D. J. Liu, G. M. Peloso, H. Yu, A. S. Butterworth, X. Wang et al., Exome-wide association study of plasma lipids in >300,000 individuals, Nature Genetics, vol.49, issue.12, pp.1758-1766, 2017.

S. Rüschenbaum, K. Schwarzkopf, M. Friedrich?rust, F. Seeger, F. Schoelzel et al., Patatin?like phospholipase domain containing 3 variants differentially impact metabolic traits in individuals at high risk for cardiovascular events, Hepatology Communications, vol.2, issue.7, pp.798-806, 2018.

Y. Zhou, G. Llauradó, M. Ore?i?, T. Hyötyläinen, M. Orho-melander et al., Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2, Journal of Hepatology, vol.62, issue.3, pp.657-663, 2015.

E. Sliz, S. Sebert, P. Würtz, A. J. Kangas, P. Soininen et al., NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects, Human Molecular Genetics, vol.27, issue.12, pp.2214-2223, 2018.

C. J. Pirola and S. Sookoian, The dual and opposite role of theTM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis, Hepatology, vol.62, issue.6, pp.1742-1756, 2015.

N. Simons, A. Isaacs, G. H. Koek, S. Ku?, N. C. Schaper et al., PNPLA3, TM6SF2, and MBOAT7 Genotypes and Coronary Artery Disease, Gastroenterology, vol.152, issue.4, pp.912-913, 2017.

O. L. Holmen, H. Zhang, Y. Fan, D. H. Hovelson, E. M. Schmidt et al., Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk, Nature Genetics, vol.46, issue.4, pp.345-351, 2014.

P. Dongiovanni, S. Petta, C. Maglio, A. L. Fracanzani, R. Pipitone et al., Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease, Hepatology, vol.61, issue.2, pp.506-514, 2015.

B. K. Lauridsen, S. Stender, T. S. Kristensen, K. F. Kofoed, L. Køber et al., Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals, European Heart Journal, vol.39, issue.5, pp.385-393, 2017.

A. J. Käräjämäki, J. Hukkanen, H. Kauma, Y. A. Kesäniemi, and O. Ukkola, Metabolic syndrome but not genetic polymorphisms known to induce NAFLD predicts increased total mortality in subjects with NAFLD (OPERA study), Scandinavian Journal of Clinical and Laboratory Investigation, vol.80, issue.2, pp.106-113, 2019.

, Proteases and their inhibitors, Scandinavian Journal of Clinical and Laboratory Investigation, vol.62, issue.5, pp.76-80, 2002.

A. Unalp?arida and C. E. Ruhl, Patatin?Like Phospholipase Domain?Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population, Hepatology, vol.71, issue.3, pp.820-834, 2020.

S. Grimaudo, R. M. Pipitone, G. Pennisi, C. Celsa, C. Cammà et al., Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease, Clinical Gastroenterology and Hepatology, vol.18, issue.4, pp.935-944.e3, 2020.

V. Ormazabal, S. Nair, O. Elfeky, C. Aguayo, C. Salomon et al., Association between insulin resistance and the development of cardiovascular disease, Cardiovascular Diabetology, vol.17, issue.1, p.122, 2018.

J. T. Haas, L. Vonghia, D. A. Mogilenko, A. Verrijken, O. Molendi-coste et al., Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution, Nature Metabolism, vol.1, issue.6, pp.604-614, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02173578

N. Gehrke and J. M. Schattenberg, Metabolic Inflammation?A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease?, Gastroenterology, vol.158, issue.7, pp.1929-1947.e6, 2020.

Z. Chen, H. Qin, S. Qiu, G. Chen, and Y. Chen, Correlation of triglyceride to high-density lipoprotein cholesterol ratio with nonalcoholic fatty liver disease among the non-obese Chinese population with normal blood lipid levels: a retrospective cohort research, Lipids in Health and Disease, vol.18, issue.1, p.162, 2019.

M. H. Yang, J. Sung, and G. Gwak, The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population, Journal of Clinical Lipidology, vol.10, issue.2, pp.289-298, 2016.

F. Bril, J. J. Sninsky, A. M. Baca, H. R. Superko, P. Portillo-sanchez et al., Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD, The Journal of Clinical Endocrinology & Metabolism, vol.101, issue.2, pp.644-652, 2016.

K. Peng, Z. Mo, and G. Tian, Serum Lipid Abnormalities and Nonalcoholic Fatty Liver Disease in Adult Males, The American Journal of the Medical Sciences, vol.353, issue.3, pp.236-241, 2017.

S. Ben-aicha, L. Badimon, and G. Vilahur, Advances in HDL: Much More than Lipid Transporters, International Journal of Molecular Sciences, vol.21, issue.3, p.732, 2020.

L. Hodson and P. J. Gunn, The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state, Nature Reviews Endocrinology, vol.15, issue.12, pp.689-700, 2019.

J. T. Haas, J. Miao, D. Chanda, Y. Wang, E. Zhao et al., Hepatic Insulin Signaling Is Required for Obesity-Dependent Expression of SREBP-1c mRNA but Not for Feeding-Dependent Expression, Cell Metabolism, vol.15, issue.6, pp.873-884, 2012.

G. I. Smith, M. Shankaran, M. Yoshino, G. G. Schweitzer, M. Chondronikola et al., Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease, Journal of Clinical Investigation, vol.130, issue.3, pp.1453-1460, 2020.

J. D. Mcgarry, G. P. Mannaerts, and D. W. Foster, A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis., Journal of Clinical Investigation, vol.60, issue.1, pp.265-270, 1977.

K. H. Roumans, L. Lindeboom, P. Veeraiah, C. M. Remie, E. Phielix et al., Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance, Nature Communications, vol.11, issue.1, p.1891, 2020.
URL : https://hal.archives-ouvertes.fr/inserm-02649908

D. Zhang, X. Tong, K. Vandommelen, N. Gupta, K. Stamper et al., Lipogenic transcription factor ChREBP mediates fructose-induced metabolic adaptations to prevent hepatotoxicity, Journal of Clinical Investigation, vol.127, issue.7, pp.2855-2867, 2017.

J. Bricambert, M. Alves-guerra, P. Esteves, C. Prip-buus, J. Bertrand-michel et al., The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity, Nature Communications, vol.9, issue.1, p.2092, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02122655

C. Kim, C. Addy, J. Kusunoki, N. N. Anderson, S. Deja et al., Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation, Cell Metabolism, vol.26, issue.2, pp.394-406.e6, 2017.

M. Adiels, S. Olofsson, M. Taskinen, and J. Bore?n, Overproduction of Very Low?Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.28, issue.7, pp.1225-1236, 2008.

B. G. Nordestgaard, S. J. Nicholls, A. Langsted, K. K. Ray, and A. Tybjærg-hansen, Advances in lipid-lowering therapy through gene-silencing technologies, Nature Reviews Cardiology, vol.15, issue.5, pp.261-272, 2018.

A. Langsted, C. M. Madsen, and B. G. Nordestgaard, Contribution of remnant cholesterol to cardiovascular risk, Journal of Internal Medicine, vol.288, issue.1, pp.116-127, 2020.

E. Fabbrini, B. S. Mohammed, F. Magkos, K. M. Korenblat, B. W. Patterson et al., Alterations in Adipose Tissue and Hepatic Lipid Kinetics in Obese Men and Women With Nonalcoholic Fatty Liver Disease, Gastroenterology, vol.134, issue.2, pp.424-431, 2008.

B. Mittendorfer, M. Yoshino, B. W. Patterson, and S. Klein, VLDL Triglyceride Kinetics in Lean, Overweight, and Obese Men and Women, The Journal of Clinical Endocrinology & Metabolism, vol.101, issue.11, pp.4151-4160, 2016.

T. G. Richardson, E. Sanderson, T. M. Palmer, M. Ala-korpela, B. A. Ference et al., Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis, PLOS Medicine, vol.17, issue.3, p.e1003062, 2020.

M. K. Poulsen, B. Nellemann, H. Stødkilde-jørgensen, S. B. Pedersen, H. Grønbæk et al., Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease, The Journal of Clinical Endocrinology & Metabolism, vol.101, issue.4, pp.1637-1646, 2016.

J. N. Van-der-veen, J. P. Kennelly, S. Wan, J. E. Vance, D. E. Vance et al., The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease, Biochimica et Biophysica Acta (BBA) - Biomembranes, vol.1859, issue.9, pp.1558-1572, 2017.

C. J. Delong, Y. J. Shen, M. J. Thomas, and Z. Cui, Molecular Distinction of Phosphatidylcholine Synthesis between the CDP-Choline Pathway and Phosphatidylethanolamine Methylation Pathway, Journal of Biological Chemistry, vol.274, issue.42, pp.29683-29688, 1999.

Z. Li, L. B. Agellon, T. M. Allen, M. Umeda, L. Jewell et al., The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis, Cell Metabolism, vol.3, issue.5, pp.321-331, 2006.

A. Nakatsuka, M. Matsuyama, S. Yamaguchi, A. Katayama, J. Eguchi et al., Insufficiency of phosphatidylethanolamine N-methyltransferase is risk for lean non-alcoholic steatohepatitis, Scientific Reports, vol.6, issue.1, 2016.

S. Wan, F. Kuipers, R. Havinga, H. Ando, D. E. Vance et al., Impaired Hepatic Phosphatidylcholine Synthesis Leads to Cholestasis in Mice Challenged With a High-Fat Diet, Hepatology Communications, vol.3, issue.2, pp.262-276, 2019.

J. Simon, M. Nuñez-garcía, P. Fernández-tussy, L. Barbier-torres, D. Fernández-ramos et al., Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly, Cell Metabolism, vol.31, issue.3, pp.605-622.e10, 2020.

Y. Q. Chen, T. G. Pottanat, R. W. Siegel, M. Ehsani, Y. Qian et al., Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids, Journal of Lipid Research, vol.61, issue.8, pp.1203-1220, 2020.

A. B. Jørgensen, R. Frikke-schmidt, A. S. West, P. Grande, B. G. Nordestgaard et al., Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction, European Heart Journal, vol.34, issue.24, pp.1826-1833, 2012.

A. B. Jørgensen, R. Frikke-schmidt, B. G. Nordestgaard, and A. Tybjærg-hansen, Loss-of-function mutations in APOC3 and reduced risk of ischemic vascular disease, Atherosclerosis, vol.235, issue.2, p.e18, 2014.

B. Lung, . Institute, J. Crosby, G. M. Peloso, P. L. Auer et al., Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease, New England Journal of Medicine, vol.371, issue.1, pp.22-31, 2014.

F. E. Dewey, V. Gusarova, C. O?dushlaine, O. Gottesman, J. Trejos et al., Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease, New England Journal of Medicine, vol.374, issue.12, pp.1123-1133, 2016.

H. Niki, Y. Kishimoto, E. Saita, R. Ohmori, K. Kondo et al., Plasma Betatrophin Levels and Carotid Atherosclerosis, Disease Markers, vol.2019, pp.1-5, 2019.

N. O. Stitziel, A. V. Khera, X. Wang, A. J. Bierhals, A. C. Vourakis et al., ANGPTL3 Deficiency and Protection Against Coronary Artery Disease, Journal of the American College of Cardiology, vol.69, issue.16, pp.2054-2063, 2017.

A. Georgiadi, Y. Wang, R. Stienstra, N. Tjeerdema, A. Janssen et al., Overexpression of Angiopoietin-Like Protein 4 Protects Against Atherosclerosis Development, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.33, issue.7, pp.1529-1537, 2013.

R. Zhang, R. Zheng, Y. Mi, D. Zhou, F. Shen et al., APOC3 rs2070666 Is Associated with the Hepatic Steatosis Independently of PNPLA3 rs738409 in Chinese Han Patients with Nonalcoholic Fatty Liver Diseases, Digestive Diseases and Sciences, vol.61, issue.8, pp.2284-2293, 2016.

K. F. Petersen, S. Dufour, A. Hariri, C. Nelson-williams, J. N. Foo et al., Apolipoprotein C3 Gene Variants in Nonalcoholic Fatty Liver Disease, New England Journal of Medicine, vol.362, issue.12, pp.1082-1089, 2010.

A. Verrijken, S. Beckers, S. Francque, H. Hilden, S. Caron et al., A gene variant of PNPLA3 , but not of APOC3 , is associated with histological parameters of NAFLD in an obese population, Obesity, vol.21, issue.10, pp.2138-2145, 2013.

J. Hyysalo, I. Stojkovic, A. Kotronen, A. Hakkarainen, K. Sevastianova et al., Genetic variation in PNPLA3 but not APOC3 influences liver fat in non-alcoholic fatty liver disease, Journal of Gastroenterology and Hepatology, vol.27, issue.5, pp.951-956, 2012.

T. Niu, M. Jiang, Y. Xin, X. Jiang, Z. Lin et al., Lack of association between apolipoprotein C3 gene polymorphisms and risk of nonalcoholic fatty liver disease in a Chinese Han population, World Journal of Gastroenterology, vol.20, issue.13, p.3655, 2014.

X. Cheng, J. Yamauchi, S. Lee, T. Zhang, Z. Gong et al., APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice, Journal of Biological Chemistry, vol.292, issue.9, pp.3692-3705, 2017.

S. Caron, A. Verrijken, I. Mertens, C. H. Samanez, G. Mautino et al., Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.31, issue.3, pp.513-519, 2011.

S. Francque, A. Verrijken, S. Caron, J. Prawitt, R. Paumelle et al., PPAR? gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis, Journal of Hepatology, vol.63, issue.1, pp.164-173, 2015.

J. Borén, G. F. Watts, M. Adiels, S. Söderlund, D. C. Chan et al., Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.35, issue.10, pp.2218-2224, 2015.

Y. Yilmaz, E. Ulukaya, O. Atug, and E. Dolar, Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance, European Journal of Gastroenterology & Hepatology, vol.21, issue.11, pp.1247-1251, 2009.

I. Barchetta, F. A. Cimini, C. Chiappetta, L. Bertoccini, V. Ceccarelli et al., Relationship between hepatic and systemic angiopoietin?like 3, hepatic Vitamin D receptor expression and NAFLD in obesity, Liver International, vol.40, issue.9, pp.2139-2147, 2020.

Y. Lee, S. Lee, C. J. Lee, S. H. Kim, Y. Song et al., Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies, Scientific Reports, vol.6, issue.1, p.24013, 2016.

B. S. Hong, J. Liu, J. Zheng, W. Ke, Z. Huang et al., Angiopoietin-like protein 8/betatrophin correlates with hepatocellular lipid content independent of insulin resistance in non-alcoholic fatty liver disease patients, Journal of Diabetes Investigation, vol.9, issue.4, pp.952-958, 2018.

C. García-monzón, P. D. Petrov, E. Rey, P. Marañón, E. Del-pozo-maroto et al., Angiopoietin-Like Protein 8 Is a Novel Vitamin D Receptor Target Gene Involved in Nonalcoholic Fatty Liver Pathogenesis, The American Journal of Pathology, vol.188, issue.12, pp.2800-2810, 2018.

Y. Zhang, S. Li, W. Donelan, C. Xie, H. Wang et al., Angiopoietin-like protein 8 (betatrophin) is a stress-response protein that down-regulates expression of adipocyte triglyceride lipase, Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol.1861, issue.2, pp.130-137, 2016.

P. He, T. Jiang, X. Ouyang, Y. Liang, J. Zou et al., Lipoprotein lipase: Biosynthesis, regulatory factors, and its role in atherosclerosis and other diseases, Clinica Chimica Acta, vol.480, pp.126-137, 2018.

D. Pastori, F. Baratta, M. Novo, N. Cocomello, F. Violi et al., Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease, Journal of Clinical Medicine, vol.7, issue.11, p.378, 2018.

B. G. Nordestgaard, R. Wootton, and B. Lewis, Selective Retention of VLDL, IDL, and LDL in the Arterial Intima of Genetically Hyperlipidemic Rabbits In Vivo, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.15, issue.4, pp.534-542, 1995.

E. A. Ivanova, V. A. Myasoedova, A. A. Melnichenko, A. V. Grechko, and A. N. Orekhov, Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases, Oxidative Medicine and Cellular Longevity, vol.2017, pp.1-10, 2017.

A. Mccullough, S. F. Previs, J. Dasarathy, K. Lee, A. Osme et al., HDL flux is higher in patients with nonalcoholic fatty liver disease, American Journal of Physiology-Endocrinology and Metabolism, vol.317, issue.5, pp.E852-E862, 2019.

D. Lucero, V. Zago, G. I. López, M. Graffigna, G. H. López et al., Does non-alcoholic fatty liver impair alterations of plasma lipoproteins and associated factors in metabolic syndrome?, Clinica Chimica Acta, vol.412, issue.7-8, pp.587-592, 2011.

K. Tziomalos, V. G. Athyros, P. Paschos, and A. Karagiannis, Nonalcoholic fatty liver disease and statins, Metabolism, vol.64, issue.10, pp.1215-1223, 2015.

D. Barb and K. Cusi, Reply to ?statins and non-alcoholic steatohepatitis?, Metabolism, vol.66, pp.e3-e5, 2017.

F. Bril, P. Portillo-sanchez, R. Lomonaco, B. Orsak, J. Hecht et al., Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial, The Journal of Clinical Endocrinology & Metabolism, vol.102, issue.8, pp.2950-2961, 2017.

O. Shahab, R. Biswas, J. Paik, H. Bush, P. Golabi et al., Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality, Hepatology Communications, vol.2, issue.10, pp.1227-1234, 2018.

D. Margerie, P. Lefebvre, V. Raverdy, U. Schwahn, H. Ruetten et al., Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients, BMC Medical Genomics, vol.12, issue.1, p.80, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02154999

M. Ruscica, N. Ferri, C. Macchi, M. Meroni, C. Lanti et al., Liver fat accumulation is associated with circulating PCSK9, Annals of Medicine, vol.48, issue.5, pp.384-391, 2016.

P. F. Lebeau, J. H. Byun, K. Platko, M. E. Macdonald, S. V. Poon et al., Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing de novo PCSK9 expression in mice, Journal of Biological Chemistry, vol.294, issue.23, pp.9037-9047, 2019.

X. Huang, G. Shi, R. P. Devbhandari, A. Ke, Y. Wang et al., Low Level of Low-Density Lipoprotein Receptor-Related Protein 1 Predicts an Unfavorable Prognosis of Hepatocellular Carcinoma after Curative Resection, PLoS ONE, vol.7, issue.3, p.e32775, 2012.

P. F. Lebeau, J. H. Byun, K. Platko, A. A. Al-hashimi, ?. Lhoták et al., Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice, JHEP Reports, vol.1, issue.6, pp.418-429, 2019.

A. N. Hamlin, S. Chinnarasu, Y. Ding, X. Xian, J. Herz et al., Low-density lipoprotein receptor?related protein-1 dysfunction synergizes with dietary cholesterol to accelerate steatohepatitis progression, Journal of Biological Chemistry, vol.293, issue.25, pp.9674-9684, 2018.

E. Santo, S. M. Pires, N. M. Boesten, L. S. Gerritsen, G. Bovenschen et al., Hepatic low-density lipoprotein receptor-related protein deficiency in mice increases atherosclerosis independent of plasma cholesterol, Blood, vol.103, issue.10, pp.3777-3782, 2004.

A. Laatsch, M. Merkel, P. J. Talmud, T. Grewal, U. Beisiegel et al., Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance, Atherosclerosis, vol.204, issue.1, pp.105-111, 2009.

G. N. Ioannou, The Role of Cholesterol in the Pathogenesis of NASH, Trends in Endocrinology & Metabolism, vol.27, issue.2, pp.84-95, 2016.

X. Wang, B. Cai, X. Yang, O. O. Sonubi, Z. Zheng et al., Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis, Cell Metabolism, vol.31, issue.5, pp.969-986.e7, 2020.

L. T. Gan, D. M. Van-rooyen, M. E. Koina, R. S. Mccuskey, N. C. Teoh et al., Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent, Journal of Hepatology, vol.61, issue.6, pp.1376-1384, 2014.

N. Saeed, B. Nadeau, C. Shannon, and M. Tincopa, Evaluation of Dietary Approaches for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review, Nutrients, vol.11, issue.12, p.3064, 2019.

P. K. Luukkonen, S. Dufour, K. Lyu, X. Zhang, A. Hakkarainen et al., Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease, Proceedings of the National Academy of Sciences, vol.117, issue.13, pp.7347-7354, 2020.

A. Mardinoglu, H. Wu, E. Bjornson, C. Zhang, A. Hakkarainen et al., An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans, Cell Metabolism, vol.27, issue.3, pp.559-571.e5, 2018.

W. K. Abdelbasset, S. A. Tantawy, D. M. Kamel, B. A. Alqahtani, and G. S. Soliman, A randomized controlled trial on the effectiveness of 8-week high-intensity interval exercise on intrahepatic triglycerides, visceral lipids, and health-related quality of life in diabetic obese patients with nonalcoholic fatty liver disease, Medicine, vol.98, issue.12, p.e14918, 2019.

F. Shojaee-moradie, D. J. Cuthbertson, M. Barrett, N. C. Jackson, R. Herring et al., Exercise Training Reduces Liver Fat and Increases Rates of VLDL Clearance But Not VLDL Production in NAFLD, The Journal of Clinical Endocrinology & Metabolism, vol.101, issue.11, pp.4219-4228, 2016.

E. Vilar-gomez, Y. Martinez-perez, L. Calzadilla-bertot, A. Torres-gonzalez, B. Gra-oramas et al., Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis, Gastroenterology, vol.149, issue.2, pp.367-378.e5, 2015.

K. Promrat, D. E. Kleiner, H. M. Niemeier, E. Jackvony, M. Kearns et al., Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis, Hepatology, vol.51, issue.1, pp.121-129, 2009.

G. Lassailly, R. Caiazzo, D. Buob, M. Pigeyre, H. Verkindt et al., Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients, Gastroenterology, vol.149, issue.2, pp.379-388, 2015.

R. Caiazzo, G. Lassailly, E. Leteurtre, G. Baud, H. Verkindt et al., Roux-en-Y Gastric Bypass Versus Adjustable Gastric Banding to Reduce Nonalcoholic Fatty Liver Disease, Annals of Surgery, vol.260, issue.5, pp.893-899, 2014.

G. Lassailly, R. Caiazzo, L. Ntandja-wandji, V. Gnemmi, G. Baud et al., Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis, Gastroenterology, vol.159, issue.4, pp.1290-1301.e5, 2020.

M. Manco, A. Mosca, F. De-peppo, R. Caccamo, R. Cutrera et al., The Benefit of Sleeve Gastrectomy in Obese Adolescents on Nonalcoholic Steatohepatitis and Hepatic Fibrosis, The Journal of Pediatrics, vol.180, pp.31-37.e2, 2017.

P. Praveen-raj, R. M. Gomes, S. Kumar, P. Senthilnathan, P. Karthikeyan et al., The effect of surgically induced weight loss on nonalcoholic fatty liver disease in morbidly obese Indians: ?NASHOST? prospective observational trial, Surgery for Obesity and Related Diseases, vol.11, issue.6, pp.1315-1322, 2015.

T. Yokoyama, R. Fukai, Y. Nagai, and T. Hirata, Origin and Evolution of Distinct Isotopic Variabilities for Sr, Mo, and Nd within CC and NC Reservoirs, Goldschmidt Abstracts, 2020.

A. Schneck, R. Anty, S. Patouraux, S. Bonnafous, D. Rousseau et al., Roux-En Y Gastric Bypass Results in Long-Term Remission of Hepatocyte Apoptosis and Hepatic Histological Features of Non-alcoholic Steatohepatitis, Frontiers in Physiology, vol.7, issue.344, 2016.

A. Tailleux, K. Rouskas, F. Pattou, and B. Staels, Bariatric surgery, lipoprotein metabolism and cardiovascular risk, Current Opinion in Lipidology, vol.26, issue.4, pp.317-324, 2015.

T. D. Adams, L. E. Davidson, S. E. Litwin, J. Kim, R. L. Kolotkin et al., Weight and Metabolic Outcomes 12 Years after Gastric Bypass, New England Journal of Medicine, vol.377, issue.12, pp.1143-1155, 2017.

A. Aminian, A. Zajichek, D. E. Arterburn, K. E. Wolski, S. A. Brethauer et al., Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity, JAMA, vol.322, issue.13, p.1271, 2019.

J. Thereaux, T. Lesuffleur, S. Czernichow, A. Basdevant, S. Msika et al., Long-term adverse events after sleeve gastrectomy or gastric bypass: a 7-year nationwide, observational, population-based, cohort study, The Lancet Diabetes & Endocrinology, vol.7, issue.10, pp.786-795, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02568049

O. Chávez-talavera, A. Tailleux, P. Lefebvre, and B. Staels, Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease, Gastroenterology, vol.152, issue.7, pp.1679-1694.e3, 2017.

B. A. Neuschwander-tetri, R. Loomba, A. J. Sanyal, J. E. Lavine, M. L. Van-natta et al., Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial, The Lancet, vol.385, issue.9972, pp.956-965, 2015.

Z. M. Younossi, V. Ratziu, R. Loomba, M. Rinella, Q. M. Anstee et al., Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebocontrolled phase 3 trial, Lancet, vol.394, pp.2184-2196, 2019.

C. Labenz, J. H. Prochaska, Y. Huber, M. Nagel, B. K. Straub et al., Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low?Density Lipoprotein Cholesterol, Hepatology Communications, vol.3, issue.11, pp.1472-1481, 2019.

M. S. Siddiqui, M. L. Van-natta, M. A. Connelly, R. Vuppalanchi, B. A. Neuschwander-tetri et al., Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis, Journal of Hepatology, vol.72, issue.1, pp.25-33, 2020.

P. J. Pockros, M. Fuchs, B. Freilich, E. Schiff, A. Kohli et al., CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients, Liver International, vol.39, issue.11, pp.2082-2093, 2019.

K. Patel, S. A. Harrison, M. Elkhashab, J. F. Trotter, R. Herring et al., Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial, Hepatology, vol.72, issue.1, pp.58-71, 2020.

E. Somm and F. R. Jornayvaz, Fibroblast Growth Factor 15/19: From Basic Functions to Therapeutic Perspectives, Endocrine Reviews, vol.39, issue.6, pp.960-989, 2018.

F. Eren, R. Kurt, F. Ermis, O. Atug, N. Imeryuz et al., Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease, Clinical Biochemistry, vol.45, issue.9, pp.655-658, 2012.

S. A. Harrison, M. E. Rinella, M. F. Abdelmalek, J. F. Trotter, A. H. Paredes et al., NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, The Lancet, vol.391, issue.10126, pp.1174-1185, 2018.

S. A. Harrison, S. J. Rossi, A. H. Paredes, J. F. Trotter, M. R. Bashir et al., NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis, Hepatology, vol.71, issue.4, pp.1198-1212, 2019.

S. A. Harrison, S. J. Rossi, A. H. Paredes, J. F. Trotter, M. R. Bashir et al., NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis, Hepatology, vol.71, issue.4, pp.1198-1212, 2019.

M. E. Rinella, J. F. Trotter, M. F. Abdelmalek, A. H. Paredes, M. A. Connelly et al., Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis, Journal of Hepatology, vol.70, issue.4, pp.735-744, 2019.

M. Zhou, R. M. Learned, S. J. Rossi, H. Tian, A. M. Depaoli et al., Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis, Journal of Lipid Research, vol.60, issue.3, pp.550-565, 2019.

Y. Hao, J. Zhou, M. Zhou, X. Ma, Z. Lu et al., Serum Levels of Fibroblast Growth Factor 19 Are Inversely Associated with Coronary Artery Disease in Chinese Individuals, PLoS ONE, vol.8, issue.8, p.e72345, 2013.

P. N. Newsome, M. Palmer, B. Freilich, M. Y. Sheikh, A. Y. Sheikh et al., Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study, Journal of Hepatology, vol.73, issue.2, pp.231-240, 2020.

T. Le, J. Chen, C. Changchien, M. R. Peterson, Y. Kono et al., Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial, Hepatology, vol.56, issue.3, pp.922-932, 2012.

V. Dubois, J. Eeckhoute, P. Lefebvre, and B. Staels, Distinct but complementary contributions of PPAR isotypes to energy homeostasis, Journal of Clinical Investigation, vol.127, issue.4, pp.1202-1214, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01709972

B. Staels, M. Maes, and A. Zambon, Fibrates and future PPAR? agonists in the treatment of cardiovascular disease, Nature Clinical Practice Cardiovascular Medicine, vol.5, issue.9, pp.542-553, 2008.

K. H. Liss and B. N. Finck, PPARs and nonalcoholic fatty liver disease, Biochimie, vol.136, pp.65-74, 2017.

G. Musso, M. Cassader, E. Paschetta, and R. Gambino, Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis, JAMA Internal Medicine, vol.177, issue.5, p.633, 2017.

V. Ratziu, P. Giral, S. Jacqueminet, F. Charlotte, A. Hartemann?heurtier et al., Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial, Gastroenterology, vol.135, issue.1, pp.100-110, 2008.

V. Ratziu, F. Charlotte, C. Bernhardt, P. Giral, M. Halbron et al., Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial, Hepatology, vol.51, issue.2, pp.445-453, 2009.

G. Musso, M. Cassader, E. Paschetta, and R. Gambino, Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges, Hepatology, vol.65, issue.3, pp.1058-1061, 2017.

K. Cusi, B. Orsak, F. Bril, R. Lomonaco, J. Hecht et al., Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus, Annals of Internal Medicine, vol.165, issue.5, p.305, 2016.

F. Bril, S. Kalavalapalli, V. C. Clark, R. Lomonaco, C. Soldevila-pico et al., Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes, Clinical Gastroenterology and Hepatology, vol.16, issue.4, pp.558-566.e2, 2018.

R. B. Goldberg, D. M. Kendall, M. A. Deeg, J. B. Buse, A. J. Zagar et al., A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia: Response to Bell and Brunzell, Diabetes Care, vol.28, issue.12, pp.2985-2986, 2005.

E. Filipova, K. Uzunova, K. Kalinov, and T. Vekov, Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis, Diabetology & Metabolic Syndrome, vol.9, issue.1, p.90, 2017.

J. A. Dormandy, B. Charbonnel, D. J. Eckland, E. Erdmann, M. Massi-benedetti et al., Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial, The Lancet, vol.366, issue.9493, pp.1279-1289, 2005.

J. D. Wallach, K. Wang, A. D. Zhang, D. Cheng, H. K. Grossetta-nardini et al., Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses, BMJ, vol.368, p.l7078, 2020.

M. De-jong, H. B. Van-der-worp, Y. Van-der-graaf, F. L. Visseren, and J. Westerink, Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials, Cardiovascular Diabetology, vol.16, issue.1, p.134, 2017.

W. N. Kernan, C. M. Viscoli, and K. L. Furie, Pioglitazone After Ischemic Stroke or Transient Ischemic Attack, Journal of Vascular Surgery, vol.64, issue.1, p.260, 2016.

A. J. Sanyal, N. Chalasani, K. V. Kowdley, A. Mccullough, A. M. Diehl et al., Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis, New England Journal of Medicine, vol.362, issue.18, pp.1675-1685, 2010.

K. E. Corey, L. A. Wilson, A. Altinbas, K. P. Yates, D. E. Kleiner et al., Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial, Alimentary Pharmacology & Therapeutics, vol.49, issue.9, pp.1205-1213, 2019.

K. E. Corey, R. Vuppalanchi, L. A. Wilson, O. W. Cummings, and N. Chalasani, NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels, Alimentary Pharmacology & Therapeutics, vol.41, issue.3, pp.301-309, 2014.

G. Orasanu, O. Ziouzenkova, P. R. Devchand, V. Nehra, O. Hamdy et al., The Peroxisome Proliferator-Activated Receptor-? Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-??Dependent Manner In Vitro and In Vivo in Mice, Journal of the American College of Cardiology, vol.52, issue.10, pp.869-881, 2008.

J. Sakamoto, H. Kimura, S. Moriyama, H. Odaka, Y. Momose et al., Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by Pioglitazone, Biochemical and Biophysical Research Communications, vol.278, issue.3, pp.704-711, 2000.

H. E. Bays, S. Schwartz, T. Littlejohn, B. Kerzner, R. M. Krauss et al., MBX-8025, A Novel Peroxisome Proliferator Receptor-? Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.9, pp.2889-2897, 2011.

V. Ratziu, S. A. Harrison, S. Francque, P. Bedossa, P. Lehert et al., Elafibranor, an Agonist of the Peroxisome Proliferator?Activated Receptor?? and ??, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening, Gastroenterology, vol.150, issue.5, pp.1147-1159.e5, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02648787

M. R. Jain, S. R. Giri, B. Bhoi, C. Trivedi, A. Rath et al., Dual PPAR?/? agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models, Liver International, vol.38, issue.6, pp.1084-1094, 2017.

B. Boubia, O. Poupardin, M. Barth, J. Binet, P. Peralba et al., Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) // Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate, Journal of Medicinal Chemistry, vol.61, issue.6, pp.2246-2265

H. Staiger, M. Keuper, L. Berti, M. Hrab?-de-angelis, and H. Häring, Fibroblast Growth Factor 21?Metabolic Role in Mice and Men, Endocrine Reviews, vol.38, issue.5, pp.468-488, 2017.

A. Sanyal, E. D. Charles, B. A. Neuschwander-tetri, R. Loomba, S. A. Harrison et al., Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial, The Lancet, vol.392, issue.10165, pp.2705-2717, 2018.

Z. Lin, X. Pan, F. Wu, D. Ye, Y. Zhang et al., Fibroblast Growth Factor 21 Prevents Atherosclerosis by Suppression of Hepatic Sterol Regulatory Element-Binding Protein-2 and Induction of Adiponectin in Mice, Circulation, vol.131, issue.21, pp.1861-1871, 2015.

X. Yan, Z. Gou, Y. Li, Y. Wang, J. Zhu et al., Fibroblast growth factor 21 inhibits atherosclerosis in apoE?/? mice by ameliorating Fas-mediated apoptosis, Lipids in Health and Disease, vol.17, issue.1, p.203, 2018.

M. J. Ritter, I. Amano, and A. N. Hollenberg, Thyroid Hormone Signaling and the Liver, Hepatology, vol.72, issue.2, pp.742-752, 2020.

S. A. Harrison, M. R. Bashir, C. D. Guy, R. Zhou, C. A. Moylan et al., Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, The Lancet, vol.394, issue.10213, pp.2012-2024, 2019.

M. J. Armstrong, P. Gaunt, G. P. Aithal, D. Barton, D. Hull et al., Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study, The Lancet, vol.387, issue.10019, pp.679-690, 2016.

S. P. Marso, G. H. Daniels, K. Brown-frandsen, P. Kristensen, J. F. Mann et al., Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes, New England Journal of Medicine, vol.375, issue.4, pp.311-322, 2016.

S. P. Marso, S. C. Bain, A. Consoli, F. G. Eliaschewitz, E. Jódar et al., Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes, New England Journal of Medicine, vol.375, issue.19, pp.1834-1844, 2016.

G. Rakipovski, B. Rolin, J. Nøhr, I. Klewe, K. S. Frederiksen et al., The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE?/? and LDLr?/? Mice by a Mechanism That Includes Inflammatory Pathways, JACC: Basic to Translational Science, vol.3, issue.6, pp.844-857, 2018.

M. Nagashima, T. Watanabe, M. Terasaki, M. Tomoyasu, K. Nohtomi et al., Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice, Diabetologia, vol.54, issue.10, pp.2649-2659, 2011.

E. T. Parlevliet, Y. Wang, J. J. Geerling, J. P. Schröder-van-der-elst, K. Picha et al., GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice, PLoS ONE, vol.7, issue.11, p.e49152, 2012.

R. Loomba, Z. Kayali, M. Noureddin, P. Ruane, E. J. Lawitz et al., GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease, Gastroenterology, vol.155, issue.5, pp.1463-1473.e6, 2018.